Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression

Area of Science:

• Regenerative Medicine
• Cell Biology
• Biomaterials Science

Background:

• Mesenchymal stromal cells (MSCs) are used for bone defect repair.
• In vivo transplantation leads to temporary oxygen deprivation (hypoxia) for MSCs within scaffolds.
• Understanding hypoxia's effects on MSCs is crucial for optimizing bone regeneration therapies.

Purpose of the Study:

• To investigate the impact of temporary hypoxia on human MSC survival and osteogenic potential.
• To assess the expression of angiogenic factors following hypoxic exposure.
• To determine if hypoxia affects the bone-forming capacity of MSCs.

Main Methods:

• Primary human MSCs were exposed to temporary hypoxia (
• MSC survival, osteogenic marker gene expression (cbfa-1/Runx2, osteocalcin, type I collagen, osteopontin), and angiogenic factor (VEGF) expression were analyzed.
• Gene and protein levels of VEGF, bFGF, TGFbeta1, and IL-8 were measured post-hypoxia.

Main Results:

• Temporary hypoxia did not affect MSC survival.
• A persistent down-regulation of osteogenic markers (cbfa-1/Runx2, osteocalcin, type I collagen) was observed up to 14 days post-exposure.
• Osteopontin mRNA expression was permanently up-regulated, while VEGF expression increased significantly at both mRNA and protein levels.

Conclusions:

• Temporary hypoxia exposure in MSCs leads to reduced expression of key osteogenic markers, potentially impairing bone formation.
• While hypoxia stimulates VEGF secretion, suggesting an angiogenic response, the negative impact on osteogenesis is a significant concern.
• Optimized cell culture and transplantation strategies are needed to maintain MSC osteogenic potential in vivo.